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Running title:  
VEGF SNPs and bevacizumab response in the GeparQuinto trial 
 
Novelty & Impact Statements:  
In this pre-planned biomarker study of the neoadjuvant GeparQuinto trial, germline 
genetic variants in VEGF pathway genes were associated with bevacizumab 
treatment outcome, as assessed by pathological complete response. In particular, 
four variants in VEGFA and one variant in FLT1 were associated with treatment 
outcome. The effect of some variants seemed more pronounced in patients with 
triple-negative tumors.
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Abstract 
Studies assessing the effect of bevacizumab (BEV) on breast cancer outcome have 
shown different effects on progression-free and overall survival, suggesting that a 
subgroup of patients may benefit from this treatment. Unfortunately, no biomarkers 
exist to identify these patients. Here, we investigate whether single nucleotide 
polymorphisms (SNPs) in VEGF pathway genes correlate with pathological complete 
response (pCR) in the neoadjuvant GeparQuinto trial. 
HER2-negative patients were randomized into treatment arms receiving either BEV 
combined with standard chemotherapy or chemotherapy alone. In a pre-planned 
biomarker study, DNA was collected from 729 and 724 patients, respectively from 
both treatment arms, and genotyped for 125 SNPs. Logistic regression assessed 
interaction between individual SNPs and both treatment arms to predict pCR. 
Five SNPs may be associated with a better response to BEV, but none of them 
remained significant after correction for multiple testing. The two SNPs most 
strongly associated, rs833058 and rs699947, were located upstream of the VEGFA 
promoter. Odds ratios for the homozygous common, heterozygous and homozygous 
rare rs833058 genotypes were 2.36 (95%CI, 1.49–3.75), 1.20 (95%CI, 0.88–1.64) and 
0.61 (95%CI, 0.34–1.12). Notably, some SNPs in VEGFA exhibited a more pronounced 
effect in the triple-negative subgroup. 
Several SNPs in VEGFA may be associated with improved pCR when receiving BEV in 
the neoadjuvant setting. Although none of the observed effects survived correction 
for multiple testing, our observations are consistent with previous studies on BEV 
efficacy in breast cancer. Further research is warranted to clarify the predictive value 
of these markers. 
Key words: breast cancer, VEGF, anti-angiogenesis, bevacizumab, genetic variant, 
prognosis, biomarker, SNP 
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Introduction 
Bevacizumab (BEV), a monoclonal antibody vascular endothelial growth factor-A 
(VEGFA), was the first anti-angiogenic drug to be approved for the treatment of 
breast cancer. Although it slows the progression of metastatic breast cancer when 
combined with chemotherapy,
1-4
 the Food and Drug Administration withdrew 
approval for this indication in 2011 due to (i) a lack of evidence for a consistent 
overall survival (OS) benefit, (ii) the frequent occurrence of BEV-related toxicities, 
and (iii) the fact that there are no validated biomarkers to predict which patients 
really benefit from the therapy. 
5
 Although the therapeutic effect of BEV indeed 
appears to be modest in the metastatic breast cancer setting, the European 
Medicines Agency maintained its approval status. Similarly, recent neoadjuvant 
studies have shown a modest but significant increase in the pathological complete 
response (pCR) in HER2-negative breast cancer patients.
6, 7
 In adjuvant studies, 
however, no benefit with regard to the disease-free survival has been demonstrated 
for patients with triple-negative (TN) or HER2-positive breast cancer (BC).
8, 9
 
Markers capable of predicting the response to anti-angiogenic treatment or the 
occurrence of side effects are thus urgently needed, as this might improve patient 
selection for these patients. With regard to breast cancer subtypes, the GeparQuinto 
trial has shown that patients with triple-negative breast cancer (TNBC) appear to 
benefit more from BEV treatment than non-TNBC patients.
6
 However, this effect was 
not seen in the NSABP-B40 study.
7
 Several other biomarkers predictive of BEV 
treatment were identified in retrospective studies, including high levels of 
tumor-associated VEGF or high circulating levels of plasma VEGF.
8, 10-12
 In another 
study, gene amplifications involving VEGFA were associated with a poor outcome 
specifically in the subgroups of triple-negative and HER2-positive breast cancers.
13
 
In this study, we hypothesize that germline genetic variants underlie the response 
to the anti-angiogenic effects of BEV. Angiogenesis is a process that affects tumor 
microenvironment and by affecting vessel regression and permeability only indirectly 
affects the tumor itself. Since endothelial cells, unlike tumor cells, are not affected 
by somatic alterations, germline genetic variants could indeed explain why some 
patients respond and others do not respond to anti-angiogenic therapy. Various 
potential predictive genetic markers have been identified in clinical trials evaluating 
BEV in several tumor types,
13-19
 but these analyses — generally using single-trial 
datasets — are limited by the number of available samples, heterogeneity in the 
selection of single nucleotide polymorphisms (SNPs), and a lack of understanding of 
the functional consequences of these genetic markers. An analysis of two 
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randomized phase III trials with BEV in metastatic pancreatic adenocarcinoma 
(AViTA) and metastatic renal-cell carcinoma (AVOREN) has shown a significant 
correlation between rs9582036, a SNP in FLT1, and both PFS and OS in the BEV 
group only.
16
 Trials in metastatic colorectal cancer have also reported significant 
associations with SNPs and BEV efficacy,
14, 15
 although these results often lack 
confirmation.
17
 With respect to breast cancer, a retrospective analysis of the phase 3 
E2100 trial involving BEV revealed an association between several VEGF SNPs and 
either OS (rs699947 and rs1570360) or severe hypertension (rs2010963).
19
 In 
another single-arm trial (MO19391) including 137 women, it was confirmed that 
rs2010963 in VEGFA is related to BEV-associated toxicity, whereas rs3025039 in 
VEGFA tended to be associated with time-to-progression. A recent meta-analysis of 6 
different cancer types, including breast cancer, has also shown that several VEGF 
SNPs were predictive of PFS and also functionally relevant because they affected 
VEGFA gene expression, although observed effects were generally quite modest.
20
  
The primary aim of this study was to assess whether SNPs in VEGF pathway genes 
are associated with efficacy of bevacizumab in all patients participating to the 
neoadjuvant breast cancer study, GeparQuinto, and as a secondary aim whether 
specific breast cancer subgroups, as defined by hormone receptor status, were more 
strongly associated to specific genetic variants. 
Material and methods 
Study population 
The GeparQuinto phase III trial (NCT00567554) recruited patients with HER2-positive 
breast cancer for an anti-HER2 therapy–related study aim,
21
 and HER2-negative 
patients with the aim of testing the efficacy of BEV.
6, 22
 In the present study only 
HER2-negative patients from the GeparQuinto trial were included. The patients were 
treated with anthracycline and taxane neoadjuvant chemotherapy and were 
randomly assigned to either simultaneous treatment with bevacizumab or no 
additional therapy. In total, 1984 patients were randomly assigned in the main study. 
Germline DNA was available for 1503 of these patients. Some patients were 
excluded according to the following hierarchical order: patients without final surgery 
(n = 5), patients with >20% missing genotype, patient or tumor data (n=45). This 
resulted in a final sample size of 1453 patients. Of these patients, 729 were treated 
with bevacizumab and 724 were assigned to the control arm. The pharmacogenetic 
analysis was a preplanned biomarker substudy. All of the patients provided written 
informed consent for the pharmacogenetic analysis, and the relevant ethics 
committees at the participating study sites approved the study protocol. 
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Treatment and assessment of clinical data 
The assessment of the clinical data has been described in detail elsewhere.
6
 Briefly, 
patients included in this study were HER2-negative and scheduled to receive 
epirubicin and cyclophosphamide on day 1 and every 3 weeks for a total of four 
cycles, followed by docetaxel as well on day 1 and every 3 weeks for a total of four 
cycles. Patients were randomly assigned to receive either bevacizumab plus 
chemotherapy or chemotherapy alone. If there was no sonographical response after 
four cycles, patients were taken off treatment and continued with a different 
treatment.
23
 For the present study, however, the patients were analyzed according 
to the planned therapy intention if they received at least one cycle of chemotherapy 
or at least one cycle of BEV. All clinical and histopathological data were assessed by 
the local pathologists, including tumor stage, HER2 status, estrogen 
receptor/progesterone receptor status, and grading. Pathological reports were 
assessed and reviewed centrally for the primary study aim. For this analysis, 
pathological response was defined as pathological stage pT0 and pN0 after therapy. 
DNA extraction and genotyping 
Whole blood samples were collected in citrate-phosphate-dextrose-adenine (CPDA) 
tubes (Sarstedt AG, Nümbrecht, Germany) from patients who had consented to 
participate in the biomarker substudy. Germline DNA was extracted using the 
automated magnetic bead–based chemagic MSM I technique (PerkinElmer 
chemagen, Baesweiler, Germany) in accordance with the manufacturer’s 
instructions. Genotyping was done at the Vesalius Research Center, Leuven, Belgium 
using MassARRAY iPLEX Gold (Sequenom, San Diego, California, USA), as reported 
previously.
16
 
Selection of SNPs 
SNPs in the following 15 genes involved in the VEGF-A pathway were selected: 
VEGFA, the VEGFA homologs (placental growth factor [PGF], VEGFB, VEGFC, and 
VEGFD [also known as c-fos-induced growth factor or FIGF]), VEGF receptor-1 
(VEGFR1 or FLT1), VEGF receptor-2 (VEGFR2 or KDR), VEGF receptor-3 (VEGFR3 or 
FLT4) and the neuropilin-1 coreceptor (NRP1), regulators of hypoxia (hypoxia-
inducible factor-1α [HIF1A], HIF-2α [EPAS1], factor inhibiting HIF-1A [HIF1AN or 
FIH1], von Hippel–Lindau tumor suppressor [VHL]), and the oxygen sensors (prolyl 
hydroxylase domain-containing proteins 1 [EGLN2], 2 [EGLN1], and 3 [EGLN3]). A 
detailed description of the way in which SNPs were selected in these genes has been 
published previously.
16
 Briefly, genomic sequences 5 kb upstream of the translation 
start site and downstream of the 3′ polyadenylation site in each gene were used to 
select SNPs from the HapMap database (phase 2 public release, no. 22). Common 
SNPs with a minor allele frequency ≥ 0.1 and pairwise correlation coefficients 
VEGF SNPs and bevacizumab response in the GeparQuinto Trial 7 
 
(r
2
) ≤ 0.8 were selected using the SNP Tagger approach in the Haploview software 
package.
24, 25
 A total of 170 tagging SNPs in VEGF pathway genes, as well as 16 SNPs 
previously associated with bevacizumab efficacy or with circulating VEGF levels, 
were selected. Of these, 170 were successfully designed and genotyped 
(Supplementary Table 1). Quality control further removed 30 SNPs with a call rate of 
<95%. After exclusion of SNPs with a minor allele frequency < 0.1 in the study, a final 
set of 125 SNPs was considered for statistical analysis (Supplementary Table 1). 
Statistical analyses 
Logistic regression models were used as described below to investigate the 
association between the treatment arm and several SNPs relative to pCR. Patients 
with missing pCR information were excluded. Missing information about patient and 
tumor characteristics was imputed using single “best guesses” (median value of 
continuous predictors, the most common value of categorical or ordinal categorical 
predictors) based on non-missing data across all subjects. Missing genotype values 
were not imputed, but remained missing. Continuous predictors were used as 
natural cubic spline functions to describe nonlinear effects as recently described.
26
  
For each SNP, a logistic regression model was fitted with the outcome pCR and the 
predictors SNP (ordinal; 0, 1, 2 minor alleles), treatment arm (bevacizumab versus 
standard treatment), SNP by treatment arm interaction, as well as the established 
predictors age (continuous), body mass index (continuous), tumor stage (ordinal), 
lymph-node status (categorical; pN0 versus pN+), grading (ordinal; G1, G2, G3), 
histology (categorical; ductal, lobular, others), and hormone receptor status 
(categorical; triple-negative versus not triple-negative). The SNP by treatment arm 
interaction was included to examine whether the differences between the treatment 
arms depended on genetic variants. The interaction P values were calculated and 
then corrected using the Bonferroni–Holm method. Genotype-specific odds ratios 
(ORs) for the treatment arm, adjusted for the established predictors from above, 
were estimated for ten SNPs with the smallest uncorrected P values using the 
interaction models. 
The association between hormone receptor, genotypes, and treatment arm with 
regard to pCR was the secondary study aim. Therefore, for each of the ten SNPs with 
small interaction P values from above, the interaction model was extended by 
including the three-way interaction SNP by treatment arm by hormone receptor and 
the corresponding two-way interactions. The two models were compared using the 
Akaike information criterion (AIC). A better AIC value for the latter model suggests 
that the association of treatment and genotype differs between patients with triple-
negative tumors and patients without triple-negative tumors. In this case, hormone 
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receptor and genotype-specific ORs for the treatment arm were estimated using the 
extended regression model. 
The goodness of fit of the logistic regression models was tested using the 
Hosmer-Lemeshow χ
2
 test, where a large P value indicates good calibration. 
All of the tests were two-sided, and a P value of < 0.05 was regarded as statistically 
significant. Calculations were carried out using the R system for statistical computing 
(version 3.0.1; R Development Core Team, Vienna, Austria, 2013). 
Results 
Patient characteristics 
A total of 1453 patients were included in the analysis. Complete data for patient and 
tumor characteristics were available for 95.7% of the patients. Patients and tumor 
characteristics are shown in Table 1. pCR was correlated with all previously 
described predictors in the expected direction. Patients with a higher tumor stage 
were less likely to achieve a pCR, and patients with a negative hormone receptor 
status or a higher grading were more likely to achieve a pCR (Table 1). The patient 
characteristics were similar to those in the main study. There were no differences in 
the pCR rate between patients who took part in this study and those who did not 
(data not shown). 
Genotype results 
Genotyping results, SNP location, and P values for the Hardy–Weinberg equilibrium 
analysis are presented in Supplementary Table 1. 
The association between treatment and genotype with regard to pCR was analyzed 
using logistic regression models as described above. Ten SNPs with the smallest 
P values for SNP by treatment interaction are shown in Table 2. None of the SNPs 
were significant after correction for multiple testing. In other words, it was not 
shown that a genotype influenced the difference between the treatment arms. 
Five of these 10 SNPs are located on chromosome 6 around VEGFA, and the top hit 
is located upstream from the promoter of VEGFA (Fig. 1). Three of the SNPs were 
located on chromosome 2 around EPAS1. Two further SNPs were related to FLT1 and 
EGLN3. 
Patients with homozygous common genotypes in VEGFA or EPAS1 appeared to 
benefit from BEV treatment, whereas patients with at least one minor allele did not 
(Table 2). For example, in relation to rs833058 (VEGFA), patients with the common 
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genotype had a greater benefit from BEV treatment, with an OR of 2.36 (95% CI, 1.49 
to 3.75), whereas patients with a heterozygous or homozygous rare genotype did 
not benefit (OR for heterozygous: 1.21; 95% CI, 0.89 to 1.65; OR for homozygous 
rare: 0.62, 95% CI, 0.34 to 1.13). 
Next, the predictive association between treatment and genotype in these SNPs was 
assessed in the subgroups of hormone receptor–positive and hormone receptor–
negative patients. Since this study was performed on HER2-negative patients, all 
hormone receptor–negative patients represent TNBC patients. The treatment 
efficacy might depend on hormone receptor status in five out of 10 SNPs with the 
smallest interaction P values, with a greater effect in the group of TNBC patients 
(Table 3). Patients with a homozygous common genotype and triple-negative tumors 
appeared to benefit from BEV treatment, whereas the other patients did not. For 
example, with regard to SNP rs1374749, the effect of the common genotype on the 
drug response was much greater in triple-negative patients (OR 3.20; 95% CI, 1.68 to 
6.07) than in patients with hormone receptor–positive, HER2-negative tumors (OR 
0.91; 95% CI, 0.45 to 1.87). 
All of the logistic regression models were well calibrated. The P values in the 
Hosmer–Lemeshow tests ranged from 0.13 to 0.91, and the median value was 0.49. 
Discussion 
In this pre-planned biomarker substudy of the neoadjuvant GeparQuinto (GBG44) 
trial, germline genetic variants in VEGF pathway genes were associated with 
bevacizumab treatment response as assessed by pCR. Remarkably, out of top 10 
SNPs with the smallest P values, 5 SNPs were located in VEGFA. None of these 
remained statistically significant after adjustment for multiple testing. The effect of 
some SNPs in VEGF-A appeared to be stronger in patients with triple-negative breast 
tumors. 
A biomarker that is able to predict the efficacy of BEV is urgently needed, particularly 
for patients with breast cancer, as not all clinical trials have shown clear superiority 
for the drug. Several trials have assessed the predictive value of circulating VEGF-A 
levels in serum. Although high VEGF-A serum levels were consistently associated 
with poor prognosis, they failed as a predictive marker for BEV treatment in a meta-
analysis including colorectal, lung, breast and renal cancer patients.
27
 In addition, 
high expression levels of a VEGF-A splice variant in tumor tissue were associated 
with more favorable PFS and OS in metastatic breast cancer in a single BEV-treated 
group.
28
 Also levels of the short isoform VEGF-A, which are currently being 
prospectively validated in a phase III metastatic breast cancer trial (MERiDiAN), look 
promising as a predictive biomarker for BEV.
29
 However, despite these concerted 
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efforts using a wide range of biological sample types, a validated marker predictive 
of treatment outcome for BEV has so far not been identified. 
In the present study, homozygous carriers of the rare rs833058 variant, which 
correspond to the AA genotype, showed the strongest association with benefit from 
BEV treatment. Additional predictive SNPs in VEGF-A were intronic (rs3025030), 
located in the promoter region (rs699947) or 3’UTR region (rs3025039) of VEGF-A. 
The rs833058 SNP is in linkage (r
2
 = 0.51) with rs699947 and other SNPs in VEGF-A. 
Interestingly, AA genotype carriers of both rs833058 and rs699947 are associated 
with an upstream 18-nucleotide insertion,
30
 which has previously been linked with 
low VEGF expression levels both in vitro and in vivo.
31, 32
 In addition, expression 
quantitative trait locus (eQTL) analyses from publicly available data sources show an 
effect of rs699947 on VEGF-A expression in Caucasians (rho = 0.263; P = 0.0060)
33
, 
thus confirming that this variant is linked to VEGF-A expression. Interestingly, the AA 
genotype of rs699947 was also associated with better OS in metastatic breast cancer 
patients when treated with a combination of BEV and paclitaxel, but not with 
paclitaxel alone (E2100 study).
19
 The same genotype was associated with a better 
response to BEV in the present GeparQuinto study (OR 2.24; 95% CI: 1.31-3.84). 
A recent comprehensive study analyzed 195 SNPs in six randomized phase III trials 
testing the addition of BEV to standard chemotherapy in colorectal, pancreatic, lung, 
renal, breast, and gastric cancer, involving a total of 716 BEV treated patients and 
686 patients receiving placebo.
20
 In this analysis, genetic variants in VEGF-C, EPAS1, 
IL8RA, but also VEGF-A were predictors of treatment outcome after BEV treatment.
20
 
Out of the 195 SNPs analyzed in this meta-analysis, we analyzed 110 SNPs in the 
GeparQuinto study, which included 729 BEV treated patients and 724 control 
patients. Our study thus has a comparable sample size, but has the advantage that it 
only consists of one cancer type evaluated for a uniform endpoint in a single 
randomized study. As such, GeparQuinto is the first study, in which it is possible to 
compare a comprehensive set of SNPs for a large set of patients. Intriguingly, when 
our results are compared with those obtained in the meta-analysis,
20
 the same 
VEGF-A SNPs identified in GeparQuinto were also significant in the meta-analysis. In 
particular, AA carriers of rs833058 were also associated with prolonged PFS in the 
meta-analysis, whereas both rs3025030 and rs3025039 were significant at P<0.05 in 
the meta-analysis. Moreover, when focusing on the breast cancer trial included in 
this meta-analysis, i.e., the AVADO phase 3 trial for metastatic breast cancer, both 
rs699947 and rs3025039 were significant (P<0.05) in a treatment by interaction 
analysis.
20
  
Interestingly, the SNPs in the 3′ UTR region of VEGF-A, i.e., rs3025030 and 
rs3025039, also showed a differential effect in the molecular subgroup analysis, with 
a greater predictive effect in triple-negative patients. The VEGF-A SNPs close to the 
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promoter region did not show this effect. Bearing in mind that none of the 
interaction P values were significant after adjustment for multiple testing and that 
the effect of these SNPs on VEGF expression in unknown, this result suggests that 
the effects through which the SNPs in the promoter region and those in the 3′ UTR 
region are mediated may differ from each other. 
Finally, we also observed an association between rs7995976 in FLT1 and pCR after 
BEV. Interestingly, increased sFLT1 levels have previously been linked with poor 
outcome after anti-angiogenic therapy in several studies,
34, 35
 whereas a significant 
correlation between another genetic variant in FLT1, i.e., rs9582036, and outcome 
after BEV was observed in pancreatic and renal cell carcinoma patients. Since sFLT1 
is an endogenous anti-angiogenic factor, tumors exposed to high levels of sFLT1 are 
indeed not expected to benefit from any additional exposure to anti-angiogenic 
molecules, such as BEV. Since the functional effect of rs7995976 on FLT1 expression 
is unknown, it thus remains an outstanding question whether this variant should be 
considered a true-positive candidate biomarker for BEV treatment. In this context 
multi-tyrosinkinase inhibitors which target FLT1 might be of interest when assessing 
BEV response. There are already several clinical trials assessing the addition of 
sunitinib or sorafenib as a monotherapy after a combination of BEV with standard 
chemotherapy.
36, 37
 Unfortunately, these studies were prematurely closed because 
of an unfavorable toxicity profile. Interestingly, studies have shown that EPAS1 
(HIF2α) regulates soluble VEGF receptor-1 (sFLT1) production from macrophages, 
which contributes to the inhibition of VEGFA during angiogenesis in mouse models.
38
 
This mechanism might also explain why we observed an increased response to BEV 
treatment in homozygous carriers of the common (wild-type) alleles for 3 EPAS1 
SNPs. 
Overall this study has several strengths and limitations. Firstly, although it is one of 
the largest single-study analyses from a prospectively randomized bevacizumab trial, 
the sample size of approximately 600 patients in each treatment arm and a total of 
261 patients with pCR is still too small to identify genetic associations of modest 
effect size while correcting for multiple testing. As a result, none of the SNPs was 
statistically significant after adjustment for multiple testing. However, since several 
other studies involving breast cancer patients treated with BEV observed similar 
association signals, our results support the view that response to BEV is a complex 
genetic phenotype that requires additional studies to be carried out in this area, in 
order not to miss a signal that may have been overseen due to limited power.  
In conclusion, we failed to observe a strong association between germline genetic 
variants in VEGF pathway genes and BEV treatment outcome. However, some SNPs 
in VEGF-A, which have been shown in other studies to correlate with overall survival 
and have been shown to be associated with reduced VEGF-A expression, were 
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predictive for BEV treatment. Additional studies are therefore warranted to explore 
the effects of these variants on bevacizumab treatment outcome. 
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Table 1. Patient characteristics and distribution of pCR 
Characteristic 
No pCR pCR 
Mean (SD) or 
count (%) 
Mean (SD) or 
count (%) 
Age (year) 49.9 (10.2) 47.0 (10.1) 
BMI (kg/m²) 25.8 (4.8) 25.9 (4.7) 
Treatment arm 
 
 
 EC-T 606 (83.7) 118 (16.3) 
 ECB-TBEV 586 (80.4) 143 (19.6) 
Lymph-node status 
 
 
 cN+ 710 (83.6) 139 (16.4) 
 cN0 482 (79.8) 122 (20.2) 
Histology 
 
 
 Ductal 944 (81.2) 219 (18.8) 
 Lobular 137 (94.5) 8 (5.5) 
 Other 111 (76.6) 34 (23.4) 
Hormone receptor status 
 
 
 Negative 318 (64.0) 179 (36.0) 
 Positive 874 (91.4) 82 (8.6) 
Tumor stage 
 
 
 cT1 174 (74.4) 60 (25.6) 
 cT2 800 (81.5) 182 (18.5) 
 cT3 76 (91.6) 7 (8.4) 
 cT4 142 (92.2) 12 (7.8) 
Grading 
 
 
 G1 50 (94.3) 3 (5.7) 
 G2 691 (89.6) 80 (10.4) 
 G3 451 (71.7) 178 (28.3) 
BEV, bevacizumab; BMI, body mass index; EC, epirubicin and cyclophosphamide; pCR, pathological 
complete remission; SD, standard deviation; T, paclitaxel. 
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Table 2. Ten SNPs with the lowest P values for treatment by genotype interaction relative to pathological complete response. Odds ratios for 
bevacizumab versus standard treatment by genotype are shown 
SNP 
Major allele/ 
minor allele Gene Chr Position MAF P value
1
 
Odds ratio (95% confidence intervals) 
Homozygous 
common Heterozygous 
Homozygous 
rare 
rs833058 G/A VEGF-A 6 43764117 0.39 0.003 2.36 (1.49, 3.75) 1.21 (0.89, 1.65) 0.62 (0.34, 1.13) 
rs699947 A/C VEGF-A 6 43768652 0.50 0.032 2.24 (1.31, 3.84) 1.40 (1.04, 1.88) 0.87 (0.53, 1.45) 
rs3025039 C/T VEGF-A 6 43784799 0.17 0.040 1.71 (1.20, 2.44) 0.97 (0.62, 1.53) 0.55 (0.22, 1.41) 
rs3025030 G/C VEGF-A 6 43782850 0.16 0.041 1.72 (1.20, 2.45) 0.98 (0.62, 1.54) 0.56 (0.22, 1.42) 
rs7995976 C/A FLT1 13 28366923 0.25 0.049 1.06 (0.72, 1.56) 1.73 (1.18, 2.53) 2.82 (1.28, 6.19) 
rs4953344 T/C EPAS1 2 46325319 0.18 0.058 1.65 (1.15, 2.35) 0.95 (0.59, 1.54) 0.55 (0.21, 1.48) 
rs3768728 T/C EPAS1 2 46363652 0.15 0.067 1.61 (1.14, 2.27) 0.90 (0.52, 1.56) 0.50 (0.16, 1.54) 
rs1374749 G/A EPAS1 2 46369294 0.46 0.073 1.88 (1.16, 3.03) 1.28 (0.94, 1.72) 0.87 (0.50, 1.51) 
rs3025033 A/G VEGF-A 6 43783338 0.18 0.074 1.68 (1.17, 2.41) 1.05 (0.68, 1.61) 0.65 (0.27, 1.58) 
rs1629140 G/A EGLN3 14 33944620 0.42 0.103 1.84 (1.16, 2.93) 1.30 (0.96, 1.76) 0.92 (0.52, 1.61) 
1 
Uncorrected P value for treatment by genotype interaction based on multiple logistic regression model with the additional predictors age, body mass index, tumor stage, 
lymph-node status, histology, grading, and hormone receptor status. None of the Bonferroni–Holm corrected P values were significant: P = 0.34 for rs833058 and P = 1.00 for 
all other SNPs. 
Chr, chromosome; MAF, minor allele frequency; SNP, single nucleotide polymorphism. 
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Table 3. Hormone receptor–specific associations between treatment, genotype, and 
pathological complete response. Odds ratios for bevacizumab versus standard treatment by 
genotype are shown 
SNP
1
 HR 
Odds ratio (95% confidence intervals) 
Homozygous 
common Heterozygous 
Homozygous 
rare 
rs3025039 HR– 2.17 (1.38, 3.41) 1.04 (0.56, 1.93) 0.50 (0.14, 1.77) 
(VEGFA) HR+ 1.21(0.67, 2.16) 0.89 (0.47, 1.68) 0.66 (0.18, 2.40) 
rs3025030 HR– 2.24 (1.42, 3.53) 1.07 (0.58, 1.99) 0.52 (0.15, 1.82) 
(VEGFA) HR+ 1.16 (0.65, 2.07) 0.86 (0.46, 1.63) 0.64 (0.18, 2.33) 
rs3768728 HR– 2.36 (1.50, 3.70) 0.81 (0.39, 1.68) 0.28 (0.06, 1.23) 
(EPAS1) HR+ 0.91 (0.53, 1.57) 1.06 (0.46, 2.44) 1.22 (0.22, 6.86) 
rs1374749 HR– 3.20 (1.68, 6.07) 1.55 (1.05, 2.28) 0.75 (0.37, 1.52) 
(EPAS1) HR+ 0.91 (0.45, 1.87) 1.00 (0.62, 1.61) 1.09 (0.44, 2.71) 
rs3025033 HR– 2.21 (1.39, 3.51) 1.14 (0.63, 2.04) 0.59 (0.18, 1.96) 
(VEGFA) HR+ 1.15 (0.64, 2.09) 0.90 (0.49, 1.63) 0.70 (0.21, 2.34) 
1
 Subset of SNPs from Table 2. Only those SNPs were included for which the logistic regression model with 
hormone receptor interaction terms a had better (i.e., smaller) Akaike information criterion than the logistic 
regression model without hormone receptor interaction terms. 
Abbreviations: HR, hormone receptor; SNP, single nucleotide polymorphism. 
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Figure 1. The VEGFA gene with –log of P values for genes in the area of VEGFA (figure 
generated with LocusZoom 
39
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